Literature DB >> 24886878

Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats.

Zheng Yong1, Xiang Gao1, Wentao Ma1, Huajing Dong1, Zehui Gong1, Ruibin Su2.   

Abstract

Reversing the respiratory depression induced by carfentanil involves intravenous administration of naloxone or naltrexone, but this treatment has disadvantages. Hence, finding a more appropriate treatment to counter the depressive actions of carfentanil is needed. In the present study, with the naloxone as a control, we investigated the efficacy of nalmefene for countering the depressive actions of carfentanil. Rats were treated successively with carfentanil (10 μg/kg, i.v.) and nalmefene (9.4-150.0 μg/kg, i.m.), and the duration of loss of righting reflex (LORR) recorded. Respiratory parameters were measured in free-moving rats using a whole-body plethysmograph after rats were administered carfentanil (20 μg/kg, i.v.) and nalmefene (9.4-150.0 μg/kg, i.m.) sequentially. The parameters of arterial blood gases were also examined. Nalmefene (9.4-150.0 μg/kg, i.m.) treatment dose-dependently decreased the duration of carfentanil-induced LORR. The respiratory rate after 60 min of nalmefene (150.0 μg/kg, i.m.) treatment increased from 34.3 ± 5.3 bursts/min to 117.8 ± 18.9 bursts/min, and enhanced pause decreased from 1.1 ± 0.1 to 0.4 ± 0.1, and was close to those of normal rats. Furthermore, nalmefene (37.5-150.0 μg/kg) treatment could enable the PaO2, SaO2 and PaCO2 to approach normal levels 10 min (15 min after carfentanil injection) or 30 min (25 min after carfentanil injection) after injection. While, a single injection of naloxone (150.0 μg/kg, i.m.) only achieved partial remission of respiratory depression. These data suggest that nalmefene more effectively counters the depressive actions induced by carfentanil and is a more appropriate treatment to antagonize carfentanil toxicity compared with naloxone.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carfentanil (PubChem CID: 62156); Nalmefene (PubChem CID: 5284594)

Mesh:

Substances:

Year:  2014        PMID: 24886878     DOI: 10.1016/j.ejphar.2014.05.044

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Neuropharmacology       Date:  2019-04-06       Impact factor: 5.250

2.  Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.

Authors:  Philip Krieter; Shwe Gyaw; Roger Crystal; Phil Skolnick
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030

3.  Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Authors:  Lauren C Smith; Paul T Bremer; Candy S Hwang; Bin Zhou; Beverly Ellis; Mark S Hixon; Kim D Janda
Journal:  J Am Chem Soc       Date:  2019-06-25       Impact factor: 15.419

Review 4.  Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil.

Authors:  Nektaria Misailidi; Ioannis Papoutsis; Panagiota Nikolaou; Artemisia Dona; Chara Spiliopoulou; Sotiris Athanaselis
Journal:  Forensic Toxicol       Date:  2017-08-18       Impact factor: 4.096

5.  Hypoxia driven opioid targeted automated device for overdose rescue.

Authors:  Mohammad S Imtiaz; Charles V Bandoian; Thomas J Santoro
Journal:  Sci Rep       Date:  2021-12-31       Impact factor: 4.379

Review 6.  The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.

Authors:  Ying Han; Wei Yan; Yongbo Zheng; Muhammad Zahid Khan; Kai Yuan; Lin Lu
Journal:  Transl Psychiatry       Date:  2019-11-11       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.